Log in

Fight Childhood Cancer and Make A Difference

Research Funding

*Denotes that all funding listed has been matched by Alex’s Lemonade Stand Foundation, increasing the donation to twice the amount shown.

Click here for research funding guidelines.

  • 06/12/2019 1:15 PM | Anonymous
    • $62,500* for LSD1 Inhibition to Treat T-cell Acute Lymphoblastic Leukemia/Lymphoma

      Michael Engel, MD/PhD - University of Utah, Salt Lake City

      With our proposed experiments, we will confirm that SP-2577 kills T-AL/L cells isolated from patients and transplanted into mice. We will also devise tests that show SP-2577 “hits its target” (LSD1) and may predict which patients will respond to the drug.

    • $25,000* for Developing Targeted Immunotherapy Against Pediatric Acute Myeloid Leukemia

      Dr. Melinda Biernacki, MD - Fred Hutchinson Cancer Research Center, Seattle, WA

      To develop new T cell therapy for pediatric AML, we propose to identify AML-specific neoepitopes by merging state-of-the-art gene sequencing of leukemia-specific variants with established HLA-binding prediction algorithms and a highthroughput immune-reactivity screen.

  • 06/12/2019 12:53 PM | Anonymous
    • $75,000* for Pharmacogenomics and Drug Screening Lead to a Novel Targeted Therapy with Potent and Specific Activity Against Mouse Models of MYCN-amplified Neuroblastoma

      Anthony Faber, PhD - Virginia Commonwealth University

      Using a combination of pharmacogenomics, drug screening and gene expression data mining, we have developed a novel targeted therapy combination that is specific for MYCN-amplified neuroblastoma. The goal of this grant is to further develop a combination targeted therapy to treat high-risk neuroblastoma.
      Click Here to Read Faber Proposal

    • $75,000* for Preclinical Development of ATR Inhibitor VE-822, Delivered Systemically in Nanoparticles, for Medulloblastoma Therapy

      Timothy Gershon, M.D./Ph.D. - University of North Carolina

      This proposal will investigate the therapeutic potential of targeting the DNA damage response protein ATR for medulloblastoma therapy, using a small molecule inhibitor, VE- 822, in novel, nanoparticle formulation (pVE-822). Radiation and chemotherapy significantly extend survival for most patients with medulloblastoma, but produce significant long-term neuro-cognitive side effects.
      Click Here to Read Gershon Proposal

    • $75,000* for Small Molecule Inhibitors of ERG for Pediatric Leukemia and Sarcoma

      John Bushweller, PhD - University of Virginia, School of Medicine

      Current treatment for childhood AML, T-ALL, and Ewing’s sarcoma is limited in efficacy and has profound long- term side-effects due to the use of traditional cytotoxic agents rather than targeted drugs inhibiting specific drivers of the diseases. A targeted agent which inhibits ERG, clearly a driver of these diseases, has the potential to improve both survival and quality of life for children with AML, T-ALL, and Ewing’s sarcoma.
      Click Here to Read Bushweller Proposal

  • 06/12/2019 12:50 PM | Anonymous
    • $50,000 for Clinical Trial at Miami Children’s Hospital

      John Raghelb, M.D.

      I Care I Cure’s funding facilitated the clinical trial for 10 children with recurrent brain cancer with an innovative and novel alternative method of giving chemotherapy directly to the site of the tumor. This study will determine if infusion of chemotherapeutic agents directly into brain fluid spaces is a safe and effective method of delivering chemotherapy treatment for children with recurrent malignant brain tumors.

    • $100,000* for Development of Targeted Leukemia Inhibitors Using Nanoparticle Delivery

      Lucio Castilla, PhD - University of Massachusetts Medical School,

      Research using the targeted therapy of soluble gold nanoparticles as inert and versatile scaffolds to deliver potent leukemia inhibitors aimed at eliminating cancer cells, while having a negligible impact in normal cells.

    • $100,000* for Targeted Inhibition of the DNA Damage Response Pathway: A Novel Intervention in the Treatment of Pediatric Leukemia

      Andre Nessenzweig, PhD - National Cancer Institute

      Research based on DNA damage response proteins to target therapeutic intervention as an inhibitor. These interventions are directed at specific cells, pathways or proteins that are indicative of heightened points of vulnerability in cancers, without the use of broad spectrum approaches.

  • 06/12/2019 12:47 PM | Anonymous
    • $53,000* for Development of a Pharmacodynamic Marker of EWS-FLII Activity to Aid in the Clinical Translation of Targeted Therapies for Ewings Sarcoma

      Vanderbilt University; Patrick J. Grohar, M.D., PhD

      Research for a new therapy that targets the dominant oncogene of Ewing Sarcoma, EWS-FLI1, to improve survival rates.

    • $53,000* for Development of a Novel Mer TKI for Treatment of ALL

      Dr. Doug Graham - University of Colorado, Denver

      Research of treatment for acute lymphoblastic leukemia (ALL) by targeting Mer signals (which have been shown to contribute to ALL) with biological agent UNC2025.

    • $53,000* for Treatment of Medulloblastoma

      Margarita Gutova, M.D. - Beckman Research Institute of City of Hope

      Research for a more effective treatment for medulloblastoma (MB), using neural stem cells that produce anti-cancer drugs localized directly to MB cells to limit toxicity.

    • $53,000* for Engineering the Lymph Node Environment with Therapeutic Vaccine Depots to Combat Neuroblastoma

      Christopher M. Jewell, PhD - University of Maryland, College Park;

      Research combining direct lymph node delivery and vaccines to generate immune responses to combat neuroblastoma.

  • 06/12/2019 12:42 PM | Anonymous
    • $50,000* for Selective Inhibition of Nuclear Export as a Novel Therapeutic Strategy in AML

      Julia Etchin, PhD - Dana-Farber Cancer Institute

      To examine the current treatments for Acute Myelogenous Leukemia (AML), which often fail to induce long-term remission. Knowledge gained from this study will make a significant contribution toward identifying highly active targeted treatments for AML that are less toxic to normal tissues.
    • $50,000* for Identification and Validation of New Therapeutic Targets in Pediatric Leukemia Through an Aneuploidy-based Synthetic Lethality Screen

      Dana-Farber Cancer Institute; David Pellman, M.D.

      Research of Trisomy 8, which is abnormal number of chromosomes, that is present in 15-20% of cases of AML and MDS. Data is being analyzed to determine which genes selectively kill trisomy 8 AML cell lines.

    • $50,000* for Development of An Innovative Treatment Strategy for Neuroblastoma and Other Pediatric Tumors: A Novel Phospholipid Ester Analogue and its Multifunctional Cancer-targeting Nanoconstruct

      Mario Otto, M.D., PhD - University of Wisconsin-Madison

      Study will look at the molecule NM404 to ascertain if NM404 can target and kill neuroblastoma cells or other forms of childhood cancer cells, and to evaluate if this compound could be a new potent treatment drug.

    • $50,000* for Development of Targeted Therapies in High Risk Childhood Acute Lymphoblastic Leukemia

      The Children’s Hospital of Philadelphia; Sarah Tasian, M.D.

      Research will focus on studying blood and bone marrow samples from children with certain types of high-risk Acute Lymphoblastic Leukemia (ALL) with the goal of improving our understanding of the functional consequences of specific genetic mutations. Through this work, she hopes to improve understanding of the critical biologic mechanisms involved in these leukemias to help identify new targeted therapies for children with high-risk ALL.

  • 06/12/2019 12:38 PM | Anonymous
    • $62,500* for 131I-MIBG Imaging and Therapy for Neuroblastoma

      Kate Matthay, M.D. - University of California San Francisco;

      Research to use a new tumor-targeted therapy for neuroblastoma—131I-MIBG which can deliver radioactivity directly to the tumors. This method is more effective and less toxic than current methods which do not deliver directly to the tumors.
    • $40,000* for Mechanisms of Oncogenic Transformation by TLX1/HOX11

      Mark Yat-fung Chiang, M.D., PhD - Regents of University of Michigan

      To advance the understanding of the biology of TLX1-driven leukemogenesis so as to identify important genes that may lead to more effective and less toxic therapies as more than one third of ALL survivors suffer long-term consequences such as second cancers.

    • $40,000* for Targeted Polymeric Parthenolide Carriers to Treat Childhood AML

      Danielle Benoit, PhD - University of Rochester

      Research to develop more effective treatments for children with AML by employing a polymer delivery system that would increase the solubility of parthenolide (PTL). This would allow it to be used for leukemia therapy, as it is only soluble at around 1 mg/ml in aqueous solutions. Polymer nanoparticles used for loading a leukemia therapeutic have been successfully created and thoroughly analyzed in vitro for their potential as therapeutically relevant drug carriers in mice.

    • $40,000* for Targeting Polycomb-mediated Epigenetic Silencing in T cell Acute Lymphoblastic Leukemia

      Emmanuel Volanakis, M.D. - Vanderbilt University Medical Center

      Research to understand the molecular signals the allow leukemia cells to thrive at the expense of normal cells by observing certain signaling mechanisms.

    • $62,500* for Development of Childhood Leukemia Translational Research Program

      Lewis B. Silverman, M.D. - Dana-Farber Cancer Institute

      Research to identify, develop, and test novel treatments and outcomes for children and adolescents with ALL and AML.

  • 06/12/2019 12:26 PM | Anonymous
    • $62,500 - 131I-MIBG Imaging and Therapy for Neuroblastoma

      Kate Matthay, M.D. - University of California San Francisco

      Research to use a new tumor-targeted therapy for neuroblastoma—131I-MIBG which can deliver radioactivity directly to the tumors. This method is more effective and less toxic than current methods which do not deliver directly to the tumors.
    • $100,000 for Discovery of Inhibitors of MLL Fusion Proteins as Targeted Therapies for Pediatric Acute Leukemia

      Alfred I DuPont Hospital for Children; Andrew Napper, PhD

      Research of selective killing of leukemia cells with MLL fusions with a cell-penetrating AF4 peptide; study extended to leukemia engrafted in mice.

    • $40,000 for Targeted Polymeric Parthenolide Carriers to Treat Childhood AML

      Danielle Benoit, PhD - University of Rochester

      Research to develop more effective treatments for children with AML by employing a polymer delivery system that would increase the solubility of parthenolide (PTL). This would allow it to be used for leukemia therapy, as it is only soluble at around 1 mg/ml in aqueous solutions. Polymer nanoparticles used for loading a leukemia therapeutic have been successfully created and thoroughly analyzed in vitro for their potential as therapeutically relevant drug carriers in mice.

  • 06/12/2019 12:24 PM | Anonymous
    • $100,000 for Targeted regulation of Acetylation as Novel Therapy for Ewing’s Sarcoma

      Jeffrey Torestky, M.D. - Georgetown University

      Research found that EWS-FLI1 in Ewing sarcoma cells is only minimally or not at all regulated by acetylation. Cell lines continue to be tested for sensitivity and causes of cell death.
  • 06/12/2019 12:23 PM | Anonymous
    • $25,000 for Targeting the FLT3 Signaling Pathway in MLL-AF9 Leukemia

      Dr. Kevin Link - Cincinnati Children’s Hospital

      Anticipate a new treatment based on research that has been successful to date.
    • $25,000 for Role of Notch1 in T-cell Development and Leukemia

      Dr. Severine Chathelin - NYU

Donate Now!

Your generous donation will fund our mission to fight cancer and help the children and their families endure their daily struggles.

I Care I Cure Childhood Cancer Foundation

P.O. Box 291386 Davie, FL 33329

Contact Mercedes Holston or  786-457-2377

Copyright © 2019 I Care I Cure - All Rights Reserved.  Privacy Policy